Chinese medical device maker Zylox-Tonbridge's revenue rises 31%, aided by global expansion

ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY

20/08/2026 14:40

Overview
China medical device maker's H1 revenue rose 31.1% yr/yr, driven by device sales growth
Net profit for the period increased 47.8% yr/yr
Growth attributed to high sales in neurovascular and peripheral vascular interventional devices

Outlook
Zylox-Tonbridge aims to accelerate global expansion through dual strategy of internal growth and acquisitions
Company pursuing regulatory registration for over 62 products across more than 47 countries and regions

Result Drivers
DEVICE SALES GROWTH - Co said strong sales growth in neurovascular and peripheral vascular interventional devices drove revenue increase
NEW PRODUCT LAUNCHES - Co cited rapid adoption and commercial launch of new products in both neurovascular and peripheral vascular segments as key growth drivers
INTERNATIONAL EXPANSION - Co said accelerated global expansion and overseas sales network contributed to strong international revenue growth

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
RMB 632.04 mln
 
H1 Net Income
 
RMB 179.11 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD. is HK$32.00, about 62.4% above its August 20 closing price of HK$19.70
The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 18 three months ago

Reuters Recommended Reads
Aug 17 - China Medical System H1 revenue rises on jump in sales of innovative and exclusive products
Aug 19 - Sino Biopharmaceutical H1 revenue up 10.6% on innovative drug sales
Aug 19 - Hong Kong's Sisram Medical H1 profit falls on China injectables investments

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)